A Dose Response Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
Conditions: Chikungunya Virus Infection Interventions: Biological: VLA1553 full dose; Biological: VLA1553 half dose; Biological: Control Sponsors: Valneva Austria GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
The Growth Hormone Deficiency (GHD) Reversal Trial: effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD —a non-inferiority Randomised Controlled Trial (RCT)
DiscussionIf this study shows that a significant proportion of children with presumed I-GHD reversal generate enough GH naturally in puberty to achieve a near FH within the target range, then this new care pathway would rapidly improve national/international practice. An assumed 50% reversal rate would provide potential UK health service cost savings of £1.8–4.6 million (€2.05–5.24 million)/year in drug costs alone. This new care pathway would also prevent children from having unnecessary daily GH injections and consequent exposure to potential adverse effects.Trial registrationEudraCT number: 2020-001006-39 (Source: Trials)
Source: Trials - August 21, 2023 Category: Research Source Type: clinical trials
EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock —a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial
This study is an investigator-initiated trial supported by the German Research Foundation (DFG, DA 1209/7–1), in which 26 different centers in Germany, Switzerland, and Austria will participate over a duration of 33 months.DiscussionThis trial has substantial clinical relevance as it evaluates a promising adjunctive treatment option in refractory septic shock patients suffering from an extraordinary high mortality. A positive trial result could change the current standard of care for this septic subgroup. The results of this study will be disseminated through presentations at international congresses, workshops, and pee...
Source: Trials - April 15, 2023 Category: Research Source Type: clinical trials
Early Versus Late Ofatumumab (Kesimpta ®) Use in Austrian RMS-Patients Over 2 Years
Condition: Relapsing Multiple Sclerosis Intervention: Other: Ofatumumab Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2023 Category: Research Source Type: clinical trials
DigitalEPI - A Prospective Pilot Study
Condition: Epilepsy Interventions: Device: EEG recording with the comparator device Micromed Brain Quick; Device: EEG recording with the investigational device " Atlas with dry electrodes " clinic/specialized staff; Device: EEG recording with the investigational device " Atlas with dry electrodes " home/lay people Sponsors: Brainhero GmbH; Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, Vienna, Austria; AIT Austrian Institute of Technology GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2023 Category: Research Source Type: clinical trials
